At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Compound 451238drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating Compound 451238 for Soft-tissue Sarcoma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The objective of this trial is to assess the safety and tolerability of combining compound 451238 and radiotherapy, treating advanced STS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft-tissue Sarcoma
CountriesUnited Kingdom
CollaboratorsMerck KGaA, Darmstadt, Germany
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartNov 2018
Primary CompletionJun 2023
TodayJul 2026
First PostedJul 27, 2018
Enrollment StartNov 5, 2018
Primary CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 7.9 years ago
Interventions
Compound 451238drug
Each patient will receive compound 451238 until disease progression unacceptable toxicities.